Fatty Liver Disease Main Forums > Nonalcoholic Steatohepatitis (NASH)
NASH Is the Second Leading Indication for Liver Transplants
(1/1)
Hep Editors:
Non-alcoholic steatohepatitis (NASH) is the second most common—and fastest-growing—indication for liver transplants in the United States, according to a study in Clinical Gastroenterology and Hepatology. Moreover, among women without hepatocellular carcinoma (HCC), NASH is already the leading reason for a liver transplant.
Changing trends in obesity and the development of better treatments for viral hepatitis have altered the picture of chronic liver disease in the United States. While vaccines can prevent hepatitis B and new treatments can cure hepatitis C, the prevalence of obesity and type 2 diabetes have shot up, increasing the risk of non-alcoholic fatty liver disease (NAFLD) and NASH, its more severe form.